Your computer can help scientists search for new childhood cancer treatments

IBMMedical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process.

To accelerate the process and broaden the search, IBM is providing those scientists free access to World Community Grid, an IBM-funded and managed program which advances scientific research by harnessing computing power "donated" by volunteers around the globe. This resource is the equivalent of a free, virtual supercomputer that enables scientists to more quickly conduct millions of virtual experiments to help pinpoint promising drug candidates for further study.

The project was announced in the United States at a press conference led by Connecticut Governor Dannel Malloy, IBM, and Dr. Ching Lau of Connecticut Children’s Medical Center, Jackson Laboratory and UConn School of Medicine, who is spearheading this crowdsourced research effort in the US.

Volunteers don't provide any time, money or technical expertise to assist with this research effort, called Smash Childhood Cancer. Instead, they participate in World Community Grid by downloading and installing a free, secure app on their computer or Android devices. While otherwise idle, volunteers' devices automatically perform virtual experiments on behalf of the research team. The results are transmitted back to researchers, where they are analyzed.

Smash Childhood Cancer brings together an international team of expert researchers from Chiba University and Kyoto University in Japan; The University of Hong Kong in Hong Kong; and the Connecticut Children's Medical Center, the Jackson Laboratory, and the University of Connecticut School of Medicine in the United States.

The global initiative is led by Dr. Akira Nakagawara, an internationally renowned pediatric oncologist, molecular biologist and CEO of the Saga Medical Center KOSEIKAN, in Japan. Dr. Nakagawara used the same research approach on a previous World Community Grid project which successfully identified drug candidates for neuroblastoma, one of the most common cancers in children.

Smash Childhood Cancer expands the search for treatments for neuroblastoma, as well as other forms of childhood cancers including brain tumor, Wilms’ tumor (tumor of the kidney), germ cell tumors (which impact the reproductive and central nervous system), hepatoblastoma (cancer of the liver) and osteosarcoma (cancer of the bone).

Since 2004, IBM’s award-winning World Community Grid has provided this resource for 27 research projects in critical areas including cancer, HIV/AIDS, Zika and Ebola viruses, genetic mapping, sustainable energy, clean water, and ecosystem preservation.

To date, World Community Grid has connected researchers to half a billion U.S. dollars' worth of free supercomputing power. This resource to accelerate scientific discovery, partially hosted in IBM's cloud, has been fueled by 720,000 individuals and 440 institutions from 80 countries who have have donated more than 1 million years of computing time on over 3 million desktops, laptops and Android mobile devices. Their participation has helped identify potential treatments for childhood cancer, more efficient solar cells, and more efficient water filtration materials.

World Community Grid is enabled by Berkeley Open Infrastructure for Network Computing (BOINC), an open source software platform developed at the University of California, Berkeley.

Join World Community Grid today to enable your computer or Android device to help Smash Childhood Cancer.

For further information, please visit:
https://www.worldcommunitygrid.org

Most Popular Now

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Nearly 1 in 3 drugs found to have safety concerns …

How often are safety concerns raised about a drug after it's been approved by the FDA? Nicholas Downing, MD, of the Department of Medicine at Brigham and Women's Hospital...

Read more

Alzheimer's experts call for changes in FDA drug a…

Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," ur...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]